Join our mailing list
Print page
Scientific Program
|
Friday, February 13, 2015 |
||
|
09:00 |
Registration and Distribution of Materials |
|
|
12:00 – 14:00 |
||
| 14:00 - 14:10 |
Opening Remarks Symposium Chairmen – Ian A. Greer, UK; Benjamin Brenner, Israel |
|
|
14:10-15:45 |
SESSION 1: Venous Thromboembolism |
|
| Chairs: |
Menno V. Huisman, the Netherlands Risto Kaaja, Finland |
|
|
14:10 |
Long-term outcome of venous thromboembolism in pregnancy Per Morten Sandset, Norway |
|
|
14:35 |
Thrombotic mechanisms of paroxysmal nocturnal hemoglobinuria Anita Hill, UK |
|
|
15:00 |
New anticoagulants in the management of venous thromboembolism in women Franco Piovella, Italy |
|
|
15:25 |
Selected Oral Communications |
|
| 1-a | Rivaroxaban use in women with antiphospholipid syndrome and previous poor anticoagulation control with vitamin K antagonists; Savino Sciascia, UK | |
| 1-b | Von Willebrand syndrome and pregnancy; Ute Scholz, Germany | |
|
15:45 – 16:15 |
Coffee Break & Exhibition Visit |
|
|
16:15 – 17:50 |
SESSION 2: Cancer and Thrombosis in Women |
|
| Chairs: |
Per Morten Sandset, Norway Dominique Farge-Bancel, France |
|
|
16:15 |
Mechanisms of thrombosis in cancer patients Anna Falanga, Italy |
|
|
16:40 |
Epidemiology of cancer and thrombosis in women Manuel Monreal, Spain |
|
|
17:05 |
Guidelines for the management of cancer and thrombosis – Special aspects in women Rupert M. Bauersachs, Germany |
|
|
17:30 |
Selected Oral Communications |
|
| 2-a |
Clinical outcomes of implementing evidence-based practice on venous thromboembolism prevention for cancer patients in Qatar, a retrospective study; Shereen Elazzazy, Qatar |
|
| 2-b |
Reducing venous thromboembolic events associated with ovarian cancer: are we winning the battle? Feras Abu Saadeh, Ireland |
|
| 20:00 - 22:00 |
GET TOGETHER RECEPTION |
|
|
Saturday, February 14, 2015 |
||
|
08:30 – 10:15 |
SESSION 3: Gestational Vascular Complications |
|
| Chairs: |
Berend Isermann, Germany Anne Flem Jacobsen, Norway |
|
|
08:30 |
The role of microvesicles in placental vascular complications Anat Aharon, Israel |
|
|
08:55 |
Pharmacokinetics of low molecular weight heparin in pregnancy: implications for management and outcomes Roopen Arya, UK |
|
|
09:20 |
New studies of low molecular weight heparin in pregnancy Saskia Middeldorp, the Netherlands |
|
|
09:45 |
Selected Oral Communications |
|
| 3-a |
Role of P45-NF-E2 in regulating syncytiotrophoblast formation in human placenta; Shrey Kohli, Germany, Israel |
|
| 3-b |
The low-molecular weight heparin-associated early variations in circulating angiogenic factors predict clinical outcomes in pregnant women with treated obstetric antiphospholipid syndrome; Jean-Christophe Gris, France |
|
| 3-c |
Heparin for prevention of unexplained recurrent miscarriage in non-thrombophilic women: A multicenter randomized double-blind placebo-controlled trial; Elisabeth Pasquier, France |
|
|
10:15 – 10:45 |
Coffee Break & Exhibition Visit |
|
|
10:45 – 12:20 |
SESSION 4: Arterial Thrombosis |
|
| Chairs: |
Armando D’Angelo, Italy Jacob Rand, USA |
|
|
10:45 |
Non-coding RNAs in cardiovascular disease: mechanisms, gender aspects and therapeutic implications Thomas Thum, Germany |
|
|
11:10 |
Current insights in thrombotic microangiopathy Bernhard Lämmle, Switzerland & Germany |
|
|
11:35 |
Thrombin generation in women with cardiovascular disease Hugo ten Cate, the Netherlands |
|
|
12:00 |
Selected Oral Communications |
|
| 4-a |
Can calibrated automated thrombogram assay predict venous thrombosis in pregnancy? Siti K. Ismail, Ireland |
|
| 4-b |
Microstructure of white matter is altered in antiphospholipid syndrome: evidence from asymptomatic neurological patients; Jean-Christophe Gris, France |
|
|
12:30 - 14:30 |
||
|
14:30 – 16:15 |
SESSION 5: Bleeding in Women and Neonates |
|
| Chairs: |
Rezan Abdul-Kadir, UK Gili Kenet, Israel |
|
|
14:30 |
Bleeding disorders in women Susan Halimeh, Germany |
|
|
14:55 |
Angiogenesis in endometriosis Juan Gilabert Estellés, Spain |
|
|
15:20 |
Neonatal hemorrhage Ulrike Nowak-Göttl, Germany |
|
|
15:45 |
Selected Oral Communications |
|
| 5-a |
Immune thrombocytopenic purpura (ITP) and pregnancy – a prospective national follow-up of recommended practice on treatment and outcome; Gisela Wegnelius, Sweden |
|
| 5-b |
Fibrinogen plasma concentration before delivery is not associated with postpartum haemorrhage: A prospective observational study; Ove Karlsson, Sweden |
|
| 5-c |
The changes in rotational thromboelastometry in pregnancy and its role in assessment of haemostasis in women with Factor XI deficiency; Joanna S. Davies, UK |
|
|
16:15 – 16:45 |
Coffee Break & Exhibition Visit |
|
|
16:45 – 18:00 |
Poster Session |
|
| 20:00 |
FAREWELL DINNER (optional) |
|
|
Sunday, February 15, 2015 |
||
|
09:00 – 10:20 |
SESSION 6: Hormonal Therapy and Thrombosis |
|
| Chairs: |
Beatriz Grand, Argentina Nigel Key, USA |
|
|
09:00 |
Hormone therapy and thrombosis - epidemiology Sabine Eichinger-Hasenauer, Austria |
|
|
09:25 |
Assisted reproductive techniques and thrombosis Elvira Grandone, Italy |
|
|
09:50 |
Selected Oral Communications |
|
| 6-a |
Family history in prediction of venous thromboembolism during combined oral contraception: case–control study; Emmanuelle Le Moigne, France |
|
| 6-b |
New thrombophilic factors in patients with vascular placental complications (VPC) and pregnancy or hormonal therapy - related thrombosis? Preliminary results of the team project; Amparo Santamaria, Uruguay, Spain |
|
| 6-c |
Platelet turnover and function in oral contraceptive users; Gorana Mitic, Serbia |
|
|
10:20 – 10:50 |
Coffee Break & Exhibition Visit |
|
|
10:50 – 12:35 |
SESSION 7: Genetic Disorders and Thrombosis |
|
| Chairs: |
Paolo Simioni, Italy Ulrike Nowak-Göttl, Germany |
|
|
10:50 |
Genomics of venous thromboembolism Pierre E. Morange, France |
|
|
11:15 |
Sickle cell disease and thrombosis in pregnancy and puerperium Nigel Key, USA |
|
|
11:40 |
Management of women with Gaucher disease in the reproductive age Hanna Rosenbaum, Israel |
|
|
12:05 |
Selected Oral Communications |
|
| 7-a |
Thrombin activatable fibrinolysis inhibitor - TAFI AS a possible link between coagulation and complement activation in patients with the antiphospholipid syndrome; Aleksandra Antovic, Sweden, UK, France |
|
| 7-b |
Von Willebrand Factor and levels of VWF-cleaving protease (ADAMTS-13) in neonates may be affected by pregnancy and perinatal complications of mothers and infants; Gili Kenet, Israel |
|
| 7-c |
Prediction of venous thromboembolic related fetal losses by a new genetic risk score; Eduardo Salas, Spain |
|
|
12:35 – 13:30 |
LUNCH |
|
|
13:30 – 15:05 |
SESSION 8: Coagulation and Brain |
|
| Chairs: |
Pelle G. Lindqvist, Sweden Roland von Känel, Switzerland |
|
|
13:30 |
Acute stress effects on hemostasis Roland von Känel, Switzerland |
|
|
13:55 |
Neuropsychiatric presentations of APLA Jean-Christophe Gris, France |
|
|
14:20 |
Adverse obstetric and neonatal outcomes in women with mental disorders Silvia Hoirisch Clapauch, Brazil |
|
|
14:45 |
Selected Oral Communications |
|
| 8-a |
Selective serotonin reuptake inhibitor (SSRI) use during pregnancy increases risk of postpartum hemorrhage and anemia; Pelle G. Lindqvist, Sweden |
|
| 8-b |
Procoagulant cell-derived microparticles in pregnant patients with antiphospholipid syndrome: relationship with pregnancy outcome and thrombosis; Dolors Tàssies, Spain |
|
|
15:05 |
Concluding Remarks – Symposium Chairmen |
|
Download the Scientific Program